Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-24-0334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Gavin M Schmidt und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroglobulin, Gene Fusion, Oncogene Proteins, Fusion. Die Arbeit nennt 42 Literaturangaben. Gefördert von: NIDDK NIH HHS, University of Pittsburgh.
Abstract (Originalsprache)
Approximately 10–20% of thyroid cancers are driven by gene fusions, which activate oncogenic signaling through aberrant overexpression, ligand-independent dimerization or loss of inhibitory motifs. We identified 13 thyroid tumors with thyroglobulin ( TG ) gene fusions and aimed to assess their histopathology and the fusions’ oncogenic and tumorigenic properties. Of eleven cases with surgical pathology, 82% were carcinomas and 18% were noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP). TG fusions preserved exon(s) 1, 1–15, 1–35 or most frequently, 1–47 of TG and, based on the 3′ partner were grouped as i) involving receptor tyrosine kinases (RTKs) ( TG::FGFR1 , TG::RET , TG::ALK and TG::NTRK1 ), ii) driving aberrant DPRX and chromosome 19 microRNA cluster expression ( TG::DPRX ) or iii) involving IGF2 mRNA-binding protein ( TG::IGF2BP1 ). All 13 fusion-positive tumors exhibited strong (8.5 ± 3.3 log2-fold) 3′ partner overexpression driven by the TG promoter. Gene expression analysis revealed TG::RET - and TG::ALK -positive tumors being BRAF V600E -like and remaining tumors RAS-like. In thyroid PCCL3 cells, the TG::NTRK1 fusion demonstrated both spontaneous and ligand-associated dimerization, activated downstream MAPK, AKT and STAT3 signaling and drove xenograft tumorigenesis in nude mice. FDA-approved NTRK inhibitors entrectinib and larotrectinib effectively blocked TG::NTRK1 signaling in vitro and inhibited xenograft tumor growth in vivo . In summary, we report a spectrum of TG gene fusions as recurrent oncogenic events in thyroid cancer and NIFTP that drive strong overexpression of partner genes, frequently RTKs. The TG::NTRK1 fusion is prone to dimerization, activates oncogenic signaling, drives tumorigenesis in thyroid cells and, like other fusions involving RTKs, represents a potential therapeutic target in thyroid cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Gavin M Schmidt, Ian J Fornal, William R Doerfler, Abigail I Wald, Shannon E Keating, Marina N Nikiforova, Yuri E Nikiforov, Alyaksandr V Nikitski
Förderung
- NIDDK NIH HHS
- University of Pittsburgh
Zitieren
APA
Schmidt, G. M., Fornal, I. J., Doerfler, W. R., Wald, A. I., Keating, S. E., Nikiforova, M. N., Nikiforov, Y. E., & Nikitski, A. V. (2025). Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0334
Vancouver
Schmidt GM, Fornal IJ, Doerfler WR, Wald AI, Keating SE, Nikiforova MN, et al. Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0334
BibTeX
@article{Schmidt2025,
author = {Schmidt, Gavin M and Fornal, Ian J and Doerfler, William R and Wald, Abigail I and Keating, Shannon E and Nikiforova, Marina N and Nikiforov, Yuri E and Nikitski, Alyaksandr V},
title = {Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-24-0334}
}
EUVIMED